Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Proton Pump Inhibitors (PPI) Market

Proton Pump Inhibitors (PPI) Market Size, Share & Trends Analysis Report, By Drug Type (Omeprazole, Esomeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, Rabeprazole), By Formulation (Tablets, Capsules, Injectable PPIs, Oral Suspensions/Granules), By End User (Hospitals, Specialty Gastroenterology Clinics, Ambulatory Surgical Centers, Homecare Settings), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029839 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Proton Pump Inhibitors (PPI) market size was valued at $3.20 billion in 2025 and is projected to reach $5.31 billion by 2035, growing at a CAGR of 5.2% between 2026 and 2035. The market includes prescription and over-the-counter acid suppression therapies used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, erosive esophagitis, and Helicobacter pylori infections. Increasing prevalence of gastrointestinal disorders and rising aging population are major factors supporting market growth globally. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 20% of the US population experiences symptoms of GERD regularly. In addition, the World Health Organization (WHO) has highlighted the growing burden of digestive disorders associated with changing dietary habits and increasing obesity prevalence globally. Rising healthcare expenditure, expanding OTC drug accessibility, and increasing adoption of generic formulations are accelerating market expansion. Pharmaceutical manufacturers are focusing on advanced oral formulations, injectable therapies, and extended-release technologies between 2024 and 2026 to strengthen their market presence. Hospitals and specialty gastroenterology clinics remain dominant end users due to increasing patient admissions related to chronic acid-related gastrointestinal conditions.

Market Dynamics

Increasing Prevalence of Gastrointestinal Disorders Driving Market Growth

The increasing prevalence of gastrointestinal disorders globally is a major factor driving the proton pump inhibitors (PPI) market. According to the National Institutes of Health (NIH), gastroesophageal reflux disease affects millions of people worldwide and remains one of the most common digestive disorders requiring long-term acid suppression therapy. Rising obesity rates, changing dietary patterns, smoking, alcohol consumption, and increasing stress levels are contributing to higher incidence of GERD and peptic ulcer disease globally. In addition, the U.S. Food and Drug Administration (FDA) continues to approve advanced PPI formulations for the management of severe gastrointestinal disorders and ulcer prevention therapies. Pharmaceutical companies are expanding investments in enhanced-release formulations, OTC product portfolios, and injectable proton pump inhibitors between 2024 and 2026 to improve patient compliance and strengthen market penetration. Increasing awareness regarding gastrointestinal health and rising healthcare infrastructure development in emerging economies are further supporting strong market growth globally.

Long-Term Side Effects and Generic Pricing Pressure Limiting Market Growth

Despite strong market demand, the proton pump inhibitors (PPI) market faces challenges related to long-term side effects and pricing pressure from generic competition. Prolonged use of proton pump inhibitors has been associated with risks such as nutrient deficiencies, kidney complications, and bone fractures, leading to increasing concerns among healthcare professionals and regulatory authorities. In addition, widespread availability of low-cost generic formulations has intensified pricing competition, affecting revenue growth for branded pharmaceutical manufacturers. Regulatory scrutiny regarding prolonged acid suppression therapy usage is also influencing prescribing patterns across developed markets. Manufacturers are addressing these challenges through development of improved formulations with enhanced safety profiles and targeted drug delivery technologies. Companies are also focusing on geographical expansion, OTC product innovation, and strategic partnerships between 2024 and 2026 to strengthen profitability and improve long-term market sustainability.

Market Segmentation

  • Based on the drug type, the market is segmented into omeprazole, esomeprazole, pantoprazole, lansoprazole, dexlansoprazole, and rabeprazole.
  • Based on the formulation, the market is segmented into tablets, capsules, injectable PPIs, and oral suspensions/granules.
  • Based on the end user, the market is segmented into hospitals, specialty gastroenterology clinics, ambulatory surgical centers, and homecare settings.

Tablets Segment Leads the Market

The tablets segment holds a dominant position due to its widespread prescription usage, cost-effectiveness, and strong over-the-counter availability globally. Tablet-based proton pump inhibitors are extensively prescribed for long-term management of acid reflux disorders, ulcers, and gastrointestinal inflammation. Pharmaceutical companies have expanded generic and branded tablet portfolios between 2022 and 2026 to improve market accessibility and patient affordability. The convenience of oral administration and high patient compliance continue to support strong demand for tablet formulations. Increasing healthcare awareness and expansion of retail pharmacy networks across emerging economies are also contributing to segment growth globally.

Injectable PPIs Segment to Record Strong Growth

The injectable PPIs segment is expected to witness strong growth due to increasing hospitalization rates associated with gastrointestinal bleeding, severe ulcers, and critical acid-related complications. Hospitals and emergency care facilities are increasingly adopting intravenous proton pump inhibitor therapies for rapid acid suppression and post-surgical gastrointestinal management. Pharmaceutical manufacturers are investing in advanced injectable formulations and hospital-focused product expansion strategies between 2024 and 2026 to strengthen their gastrointestinal therapeutic portfolios. Rising healthcare infrastructure investments and increasing adoption of critical care gastrointestinal therapies across Asia-Pacific and Middle Eastern countries are further expected to support rapid segment growth during the forecast period.

Regional Outlook

The global Proton Pump Inhibitors (PPI) market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the proton pump inhibitors (PPI) market due to the high prevalence of gastrointestinal disorders and advanced pharmaceutical infrastructure. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GERD affects nearly 20% of adults in the US, increasing long-term demand for acid suppression therapies. Rising healthcare expenditure, increasing OTC drug adoption, and strong presence of leading pharmaceutical manufacturers are supporting market growth across the country. The U.S. Food and Drug Administration (FDA) continues to support the approval and commercialization of advanced gastrointestinal therapies, further strengthening market expansion. Increasing hospital admissions related to acid reflux disorders and gastrointestinal complications are also supporting demand for prescription and injectable proton pump inhibitors.

China to Record Strong Growth

China is expected to witness strong growth due to expanding pharmaceutical manufacturing capabilities and increasing gastrointestinal disease burden. According to the World Health Organization (WHO), changing dietary patterns and increasing urbanization have contributed to rising digestive health complications across Asia-Pacific. China’s healthcare modernization initiatives and growing pharmaceutical investments are accelerating market growth. Increasing accessibility of generic medications, expanding hospital infrastructure, and rising healthcare awareness are encouraging adoption of proton pump inhibitors across the country. Pharmaceutical manufacturers are also strengthening local production facilities and distribution networks between 2024 and 2026 to improve regional market penetration and meet growing consumer demand.

Competitive Landscape

The proton pump inhibitors (PPI) market is highly competitive, with companies focusing on formulation innovation, OTC expansion, and geographical growth strategies. Key players such as AstraZeneca, Takeda Pharmaceutical Company, Pfizer, Eisai Co., Ltd., and Sanofi are strengthening their gastrointestinal treatment portfolios through strategic collaborations, manufacturing expansion, and advanced drug delivery technologies. Companies are increasingly investing in hospital-focused injectable therapies, extended-release oral formulations, and global distribution network expansion to improve market positioning. Increasing competition from generic drug manufacturers is also encouraging innovation in differentiated product development and patient-centric gastrointestinal treatment solutions.

Recent Developments

  • In May 2026, Phathom Pharmaceuticals highlighted new clinical and real-world data for VOQUEZNA® (vonoprazan) at the Digestive Disease Week (DDW) 2026 annual meeting. The company presented findings across multiple studies to strengthen clinical adoption of its first-in-class potassium-competitive acid blocker (PCAB) for GERD treatment and reinforce its position in the gastrointestinal therapeutics market.
  • In April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion. The acquisition is expected to strengthen Sun Pharma’s global pharmaceutical presence, expand its women’s health and biosimilars portfolio across more than 140 countries, and position the combined company among the top 25 pharmaceutical companies globally.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global proton pump inhibitors (PPI) market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Proton Pump Inhibitors (PPI) Market Sales Analysis – Drug Type | Formulation | End User ($ Million)
  • Proton Pump Inhibitors (PPI) Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Proton Pump Inhibitors (PPI) Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Proton Pump Inhibitors (PPI) Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Proton Pump Inhibitors (PPI) Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Proton Pump Inhibitors (PPI) Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Proton Pump Inhibitors (PPI) Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Proton Pump Inhibitors (PPI) Market Revenue and Share by Manufacturers

  • Proton Pump Inhibitors (PPI) Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 AstraZeneca

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Takeda Pharmaceutical Company

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Pfizer

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Eisai Co., Ltd.

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Sanofi

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Proton Pump Inhibitors (PPI) Market Sales Analysis by Drug Type ($ Million)

5.1 Omeprazole

5.2 Esomeprazole

5.3 Pantoprazole

5.4 Lansoprazole

5.5 Dexlansoprazole

5.6 Rabeprazole

  1. Global Proton Pump Inhibitors (PPI) Market Sales Analysis by Formulation ($ Million)

6.1 Tablets

6.2 Capsules

6.3 Injectable PPIs

6.4 Oral Suspensions/Granules

  1. Global Proton Pump Inhibitors (PPI) Market Sales Analysis by End User ($ Million)

7.1 Hospitals

7.2 Specialty Gastroenterology Clinics

7.3 Ambulatory Surgical Centers

7.4 Homecare Settings

  1. Regional Analysis

8.1 North American Proton Pump Inhibitors (PPI) Market Sales Analysis – Drug Type | Formulation | End User ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Proton Pump Inhibitors (PPI) Market Sales Analysis – Drug Type | Formulation | End User ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3 Asia-Pacific Proton Pump Inhibitors (PPI) Market Sales Analysis – Drug Type | Formulation | End User ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Proton Pump Inhibitors (PPI) Market Sales Analysis – Drug Type | Formulation | End User ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Alkem Laboratories

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Amneal Pharmaceuticals

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 Apotex Inc.

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 Aristo Pharmaceuticals

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 Aurobindo Pharma

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 Cipla Ltd.

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 Dr. Reddy’s Laboratories

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 Glenmark Pharmaceuticals

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9 Haleon

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Hetero Drugs

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 Hikma Pharmaceuticals

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Intas Pharmaceuticals

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Johnson & Johnson

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 Lupin Limited

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Macleods Pharmaceuticals

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Sandoz

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Sun Pharmaceutical Industries

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Torrent Pharmaceuticals

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Wockhardt

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 Zydus Lifesciences

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Proton Pump Inhibitors (PPI) Market Research and Analysis by Drug Type, 2026–2035 ($ Million)

2. Global Omeprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

3. Global Esomeprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

4. Global Pantoprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

5. Global Lansoprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

6. Global Dexlansoprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

7. Global Rabeprazole Market Research and Analysis by Region, 2026–2035 ($ Million)

8. Global Proton Pump Inhibitors (PPI) Market Research and Analysis by Formulation, 2026–2035 ($ Million)

9. Global Tablets Market Research and Analysis by Region, 2026–2035 ($ Million)

10. Global Capsules Market Research and Analysis by Region, 2026–2035 ($ Million)

11. Global Injectable PPIs Market Research and Analysis by Region, 2026–2035 ($ Million)

12. Global Oral Suspensions/Granules Market Research and Analysis by Region, 2026–2035 ($ Million)

13. Global Proton Pump Inhibitors (PPI) Market Research and Analysis by End User, 2026–2035 ($ Million)

14. Global Proton Pump Inhibitors (PPI) Market for Hospitals Research and Analysis by Region, 2026–2035 ($ Million)

15. Global Proton Pump Inhibitors (PPI) Market for Specialty Gastroenterology Clinics Research and Analysis by Region, 2026–2035 ($ Million)

16. Global Proton Pump Inhibitors (PPI) Market for Ambulatory Surgical Centers Research and Analysis by Region, 2026–2035 ($ Million)

17. Global Proton Pump Inhibitors (PPI) Market for Homecare Settings Research and Analysis by Region, 2026–2035 ($ Million)

18. Global Proton Pump Inhibitors (PPI) Market Research and Analysis by Region, 2026–2035 ($ Million)

19. North America Proton Pump Inhibitors (PPI) Market Research and Analysis by Country, 2026–2035 ($ Million)

20. North America Proton Pump Inhibitors (PPI) Market Research and Analysis by Drug Type, 2026–2035 ($ Million)

21. North America Proton Pump Inhibitors (PPI) Market Research and Analysis by Formulation, 2026–2035 ($ Million)

22. North America Proton Pump Inhibitors (PPI) Market Research and Analysis by End User, 2026–2035 ($ Million)

23. Europe Proton Pump Inhibitors (PPI) Market Research and Analysis by Country, 2026–2035 ($ Million)

24. Europe Proton Pump Inhibitors (PPI) Market Research and Analysis by Drug Type, 2026–2035 ($ Million)

25. Europe Proton Pump Inhibitors (PPI) Market Research and Analysis by Formulation, 2026–2035 ($ Million)

26. Europe Proton Pump Inhibitors (PPI) Market Research and Analysis by End User, 2026–2035 ($ Million)

27. Asia-Pacific Proton Pump Inhibitors (PPI) Market Research and Analysis by Country, 2026–2035 ($ Million)

28. Asia-Pacific Proton Pump Inhibitors (PPI) Market Research and Analysis by Drug Type, 2026–2035 ($ Million)

29. Asia-Pacific Proton Pump Inhibitors (PPI) Market Research and Analysis by Formulation, 2026–2035 ($ Million)

30. Asia-Pacific Proton Pump Inhibitors (PPI) Market Research and Analysis by End User, 2026–2035 ($ Million)

31. Rest of the World Proton Pump Inhibitors (PPI) Market Research and Analysis by Region, 2026–2035 ($ Million)

1. Global Proton Pump Inhibitors (PPI) Market Share by Drug Type, 2026 Vs 2035 (%)

2. Global Omeprazole Market Share by Region, 2026 Vs 2035 (%)

3. Global Esomeprazole Market Share by Region, 2026 Vs 2035 (%)

4. Global Pantoprazole Market Share by Region, 2026 Vs 2035 (%)

5. Global Lansoprazole Market Share by Region, 2026 Vs 2035 (%)

6. Global Dexlansoprazole Market Share by Region, 2026 Vs 2035 (%)

7. Global Rabeprazole Market Share by Region, 2026 Vs 2035 (%)

8. Global Proton Pump Inhibitors (PPI) Market Share by Formulation, 2026 Vs 2035 (%)

9. Global Tablets Market Share by Region, 2026 Vs 2035 (%)

10. Global Capsules Market Share by Region, 2026 Vs 2035 (%)

11. Global Injectable PPIs Market Share by Region, 2026 Vs 2035 (%)

12. Global Oral Suspensions/Granules Market Share by Region, 2026 Vs 2035 (%)

13. Global Proton Pump Inhibitors (PPI) Market Share by End User, 2026 Vs 2035 (%)

14. Global Proton Pump Inhibitors (PPI) Market for Hospitals Share by Region, 2026 Vs 2035 (%)

15. Global Proton Pump Inhibitors (PPI) Market for Specialty Gastroenterology Clinics Share by Region, 2026 Vs 2035 (%)

16. Global Proton Pump Inhibitors (PPI) Market for Ambulatory Surgical Centers Share by Region, 2026 Vs 2035 (%)

17. Global Proton Pump Inhibitors (PPI) Market for Homecare Settings Share by Region, 2026 Vs 2035 (%)

18. Global Proton Pump Inhibitors (PPI) Market Share by Region, 2026 Vs 2035 (%)

19. US Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

20. Canada Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

21. UK Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

22. France Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

23. Germany Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

24. Italy Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

25. Spain Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

26. Russia Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

27. India Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

28. China Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

29. Japan Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

30. South Korea Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

31. Australia & New Zealand Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

32. ASEAN Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

33. Middle East & Africa Proton Pump Inhibitors (PPI) Market Size, 2026–2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market was valued at $3.20 billion in 2025 and is projected to reach $5.31 billion by 2035.
The market is expected to grow at a CAGR of 5.2% between 2026 and 2035.
The tablet formulation segment dominates due to its widespread prescription usage and OTC availability globally.
North America leads due to high prevalence of gastrointestinal disorders and strong pharmaceutical infrastructure.
Injectable PPIs are expected to witness the fastest growth due to rising hospital admissions for severe gastrointestinal complications.